Investorideas.com - Cannabis Stock News: Bhang (CSE: BHNG) (OTCQX: BHNGF) Announces Debt Settlement and New Credit Facility with Cannabis Growth Opportunity Corporation
Get the latest Cannabis and Hemp stock news from www.investorideas.com
Monday, July 20, 2020
Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 443 (TSXV: $IGX.V) (OTCQB: $IGXT) (CSE: $BEV.C)(OTCQB: $WRHLF)
Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 443 (TSXV: $IGX.V) (OTCQB: $IGXT) (CSE: $BEV.C)(OTCQB: $WRHLF)
Delta, Kelowna, BC, July 20, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Read this in full at https://www.investorideas.com/news/2020/cannabis-potcasts/07201IGX-BEV-WRHLF.asp
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we look at a few public and private company announcements.
IntelGenx Corp. (TSX-V:IGX)(OTCQB:IGXT) today announced that it and Tilray, Inc. have amended the exclusivity terms of their November 2018 license, development and supply agreement to allow for IntelGenx’s co-development and commercialization of CBD products with additional partners. In consideration, IntelGenx shall pay a royalty to Tilray on all CBD products sold pursuant to this amendment. All other terms of the Agreement, including those pertaining to Tilray’s exclusive, worldwide marketing and distribution rights for non-CBD cannabis-infused VersaFilm®, remain unchanged.
“Since obtaining our cannabis micro-processing license from Health Canada a few weeks ago, we have received numerous expressions of interest from cannabis industry players in our drug delivery platforms and manufacturing capabilities, as we continue to have the only Health Canada licensed and GMP compliant facility for pharmaceutical film manufacturing,” commented Dr. Horst G. Zerbe, CEO of IntelGenx. “While we continue to work with Tilray® to align on the timing of a potential commercial launch of our first co-developed cannabis-infused VersaFilm® product, we are now actively seeking other potential partners to commercialize CBD-containing film products targeting the health and wellness market in Canada.”
Ikänik Farms, Inc. announced that Pideka SAS, a wholly owned Colombian subsidiary of the Company, has signed a collaborative agreement with CAS Biotechnology, for cannabis research on the potential medical benefits in the treatment of COVID-19, with pharmaceutical grade cannabis oil provided by the company's GACP and GMP-Pharma certified Casa Flores facility, located outside of Bogota, Colombia. The company's cannabis is supported by agronomically certified genetics and is currently sold in Colombia for use in Formula Magistral.
"We are excited to partner with CAS Biotechnology on the first export of pharmaceutical grade Cannabis to Mexico, in hopes to aid in the treatment of COVID-19," said Borja Sanz de Madrid, President of Ikänik International.
The testing will be conducted by CAS Biotechnology's scientific team at their research facility in Mexico. CAS Biotechnology's team is comprised of scientists with expertise in molecular and synthetic biology, bioinformatics, genomics, proteomics, and pre-clinical trials. Pideka will provide samples to CAS Biotechnology for conducting scientific research and pre-clinical trials to determine the effect of Cannabis oil on SARS-CoV-2's replication cycle.
"We are very proud to participate in a study that brings medicine and cannabis closer together, in a joint effort to discover possible Phyto therapeutic treatments, as a new course of action for the treatment of COVID-19," said Brian Baca, CEO of Ikänik Farms.
BevCanna Enterprises Inc. (CSE: BEV) (OTC: BVNNF) announced today that it has entered into a non-binding letter of intent to manufacture white-label CBD and THC-infused beverages for rising British Columbian beverage brand State B Beverage Co. Launched by well-known B.C. mixologist and Master Drink Maker Kelly Ann Woods, State B is part of the Brujera Elixirs Incorporated house of brands which currently includes Boozewitch (sober-curious mixers) and three additional functional human performance drinks in development.
Under the proposed agreement, BevCanna will leverage its extensive experience developing and launching beverages in the Canadian market to create the new State B beverage concept, which will be a merge of functional beverages and cannabis drinks. BevCanna will also maintain responsibility for regulatory compliance with Health Canada.
State B will hold responsibility for national sales and marketing efforts to launch the product line in Canada. The white label agreement will be for an initial term of three years with a subsequent three-year renewal option.
"The State B brand is an intriguing new concept, and we're excited to be the ones to launch the new line," said John Campbell, Chief Strategic Officer at BevCanna. "Our plan to create a sustainable consistent revenue stream through our white-label portfolio is well on track, and adding the State B brand will add to the momentum."
"BevCanna's experience in formulating functional yet very appealing beverages was exactly what we were looking for in a white-label partner," said Kelly Ann Woods, CEO of Brujera. "Their success in bringing great concepts to life, while maintaining strict regulatory compliance, convinced us that they were the right partner to work with on our new brand."
World High Life (OTCQB: WRHLF) announced having seen considerable sales numbers lead to two substantial quarters of growth from its wholly owned subsidiary, Love Hemp. Tony Calamita, the Chief Executive Officer (CEO) of Love Hemp, a London-based CBD company spearheading the development of the United Kingdom’s (UK) leading range of trusted CBD products, has the company hitting on all cylinders as it heads into the second half of the year.
Although the global COVID-19 crisis has many businesses treading water and searching for answers, Love Hemp hasn’t missed a beat while meeting these trying times head on, the company has thrived by giving customers exactly what they want—plenty of online options and continued product development.
Love Hemp has over 80 products, including oils, sprays, edibles, cosmetics, and vapes, and the company currently enjoys around 1,200 retail listings, but World High Life’s subsidiary has no plans of stopping there. Love Hemp prides itself on understanding market demand and developing new products and brands that satisfy what consumers want most. Calamita says that new product development is at the heart of everything the company does. “We currently have 15 new products in the development stage, and we remain committed to creating the UK’s leading range of trusted CBD products.”
Last week, one of those newly developed brands was launched into the market. World High Life announced Love Hemp’s new brand, Buzz Leaf, a host of products aimed at younger consumers that include the release of four broad-spectrum CBD infused e-liquids with added terpenes, and eventually the launch of a full range of CBD products, including CBD oils and capsules. According to the company, the e-liquids feature exotic flavors that contain 500mg of CBD.
Given the exponential growth that the company’s e-commerce business has seen and the sheer number of customers, who are not only finding Love Hemp online but continuing to come back again and again, Love Hemp has redesigned its global online retailer, https://www.CBDOilsUK.com, a premium CBD oil and cannabidiol supplier in the UK, to handle the overwhelming demand. Calamita says that with the launch of the Buzz Leaf products, there is now something for everyone on the website.
Tony Calamita, discussing the successful results that Love Hemp has enjoyed in Q1 and Q2 said, “The COVID-19 pandemic affected consumer markets and is accelerating existing trends within the consumer sector. When the pandemic began, we saw a shift in retail, which resulted in the acceleration of the e-commerce market as consumer demand shifted to shopping online.
“As a result, we achieved a 107% increase in online sales from January to May 2020. This was an incredibly strong period of sales for Love Hemp, and while our strong growth usually comes from a wider variety of sales channels, given the challenging business circumstances, our shift to the expansion of our online products has enabled us to ensure our customers are able to continue to purchase and to engage with us. We are focused on building trust and credibility with our consumer base and to continue to innovate while responding to evolving consumer demands.”
Sales of the company’s CBD oil, CBD oil sprays, and CBD soft gel capsules are leading the way, but the timely introduction of another new product, Love Hemp Immune, well ahead of schedule, is already growing in popularity among customers. Love Hemp Immune is advertised as a blend of CBD, essential vitamins, including vitamins C and D, and bilberry extract to maintain a healthy immune system by supporting our body’s natural defenses.
Calamita added, “We’ve also seen a greater interest in health and wellness as COVID-19 reinforced the importance of being healthy and maintaining a strong, balanced immune system.
“Since its launch, Love Hemp Immune has been well received by consumers. It was a product that was due to launch in the Winter of 2020, but, instead, we worked around the clock to ensure that consumers could have access to it much sooner as COVID-19 and a nationwide lockdown hit the UK, a time when boosting our immune systems has rarely felt more urgent. It contains the perfect combination of beneficial ingredients to help boost the body’s natural defenses. The importance of being flexible and agile while responding to consumer needs has never been more crucial.”
So, where does World High Life’s subsidiary go in the second half of the year? The announcement of the Buzz Leaf brand is certainly a good start and defines what is likely Love Hemp’s plan to get those 15 products/brands that are in development to market. Love Hemp’s CEO says, “As retail stores begin to reopen, we’re focused on holistic growth across all channels from retail to online. We are in conversations with all major retailers in the UK, and we look forward to continued growth among our customer base, while maintaining brand loyalty among consumers.”
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Contact Investorideas.com
800 665 0411
Friday, July 17, 2020
Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 442 (OTC: $VSYM) (TSX: $KHRN.TO)
Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 442 (OTC: $VSYM) (TSX: $KHRN.TO)
Delta, Kelowna, BC, July 17, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we look at a few public and private company announcements.
View Systems, Inc.’s (OTC: VSYM) Sannabis S.A.S. announced that they will meet today with students and faculty from the University of Cauca to implement their internship program established through a Collaboration Agreement # 25-32.8-010 with Sannabis’ Taller Libre Community Association. University of Cauca was founded in 1827 as the University of Popayan and later changed name to Universidad del Cauca in 1884.
This agreement with the University allows Sannabis to approach major food and medical corporations that want to enter the cannabis space but are limited by research.
The Internship Program will cover the following areas:
- Research projects on the medicinal properties of Sannabis products, application of the products, protocols for product certification, dosing protocol for diseases, and research that derives from the projects of companies that support this initiative. (Health Sciences Faculty).
- Research projects on the benefits of cosmetic products. (Faculty of Engineering)
- Research projects of social impacts, in the development of community proposals, derived from the process of cultivation, transformation, commercialization and application of products.
- Research, production and development projects in the process of , psychoactive (THC) and non-psychoactive (CBD) cultivation, cultivation for flower, seed, stems, and comprehensive use of cannabis (Faculty of Agricultural Sciences).
- Cannabis regulation. (Faculty of Law, political and social sciences)
Sannabis previously announced a site visit of their Seed Propagation Facility near
Popayan-CAUCA by the Colombian Institute of Agriculture (ICA) on July 30, 2020 at 9am. ICA will inspect, make recommendations, and give the Company 60 days to comply, after which the approval process begins. Sannabis applied for this license prior to December 31, 2018, the deadline for new applications, after this date no more applications are being accepted. Arguably a Colombian Seed Use License could be the most sought after and valuable marijuana license anywhere in the World.
The University of Cauca will certify Sannabis products as well as the Sannabis Cultivars from their seed bank. Students will also study the dosification and efficacy of Sannabis products giving the Company a huge advantage over competitors.
“I don’t believe many Cannabis products on the shelves in the U.S. and elsewhere have been analyzed and certified by a 190-year-old University. Dosage has always been an issue with consumers since it’s anecdotal and until now wasn’t backed by research, right now it’s trial and error to find the dosage that works for you,” stated John Campo, President of View Systems, Inc. and Sannabis co-founder.
“We’re proud to be working with the University in my hometown,” stated Juan Paulo Guzman, co-founder and Director of Sannabis. “Several other much bigger companies were after this relationship and we’re happy the University recognized our 23 years working with the community making quality products and promoting a new livelihood,” continued Mr. Guzman.
Students will work with Sannabis’ ongoing projects focusing on Medical and Social Components of Sannabis products and other initiatives that involve the integral use of cannabis, taking into account the aforementioned and being aware of the importance of each of the academic disciplines in all processes.
Sannabis has been working in Cauca, Colombia’s top marijuana growing region for over 23 years, educating Indigenous tribes and locals on the health benefits of the legitimate use of marijuana. Cauca is home to landrace strains made famous by a documentary chronicling a futile attempt by a European seed bank to take these strains out of Colombia.
To view a timeline of Sannabis’ 23-year history in Cauca, visit https://www.tallerlibre.org/historia
NuggMD, the nation's leading medical marijuana telemedicine platform, announced that it is now providing telemedicine services to patients in Ohio for $139.
Ohio normally prohibits the use of telemedicine for medical marijuana evaluations, but has lifted this restriction for the duration of the pandemic emergency orders. This makes it possible for patients to get their MMJ recommendation without risking exposure to Sars-COV-2.
"We're so excited to join Ohio's medical marijuana community," says Alex Milligan, NuggMD Co-Founder and CMO. "We hope that Ohio will see the benefit of allowing medical marijuana telemedicine services to continue for the long term. Even after the pandemic is over, and we don't know how long this will take, telemedicine is an incredibly valuable tool for at-risk patients."
"COVID-19 is forcing the medical community to re-consider their long-standing prejudices against telemedicine," says Kam Babazade, NuggMD Co-Founder and COO. "The misperception that patients can't receive the same quality of care and follow up via telemedicine has forced immunocompromised patients to risk exposure to illness in order to comply with local state laws. After the pandemic is over, these patients will face the same unnecessary risks to their health. We hope the state will consider making this change to their policy permanent for the well-being of at-risk cannabis patients across the state."
The state has not yet determined when the emergency orders for COVID-19 will be lifted. Recently, several states have seen a resurgence of the virus and have taken measures to increase social distancing again.
At the time this press release was written, Ohio had 46,970 confirmed cases of COVID-19, 7,681 hospitalizations and 2,807 total deaths. This total reflects a spike in confirmed cases over the final weekend of June. Those at the highest risk of contracting the virus are advised by authorities to remain at home as much as possible.
An Ohio medical marijuana evaluation with NuggMD costs just $139. As always, patients who are not approved for a medical marijuana recommendation receive their evaluation for free.
Since 2016, NuggMD has helped more than 600,000 patients connect face-to-face with their MMJ doctors via video telemedicine in California, New York, Nevada, Oklahoma and Missouri. NuggMD's practitioners provide medical marijuana recommendations to patients only in states for which they are fully-licensed to practice medicine. They are also approved to provide recommendations by their respective regulatory agencies where necessary.
Tidal Health Solutions Ltd., a privately held Licensed Producer (LP) and one of Canada's leading suppliers of Cannabis 2.0 products, announced that it is now supplying topical cannabis products in Canada.
"Our topical products are the result of extensive research and development and are leading the category in Canada", said Mark E. Burton, President and CEO of Tidal Health Solutions. "We are one of the few Licensed Producers providing these products".
Tidal's RIVA brand focuses on the benefits of cannabidiol (CBD) while the TULLIA brand features equal amounts of CBD and tetrahydrocannabinol (THC). Both come in 200mg and 400mg cannabinoids per jar formats. They are both fast absorbing lotions with a natural eucalyptus extract that provide a pleasant cooling sensation similar to a cool ocean breeze.
"In my clinical experience, well-developed topicals may be useful for conditions close to the skin's surface such as arthritis and neuropathic pain", said Dr. Douglas Smith, a founder of Tidal Health Solutions and a national expert in the medical use of cannabis. "They are very pleasant and easy to use".
The products are now available in Ontario, New Brunswick, Nova Scotia, Saskatchewan and will soon be available in Prince Edward Island and Alberta.
Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF), a vertically integrated cannabis leader with core operations in Latin America and Europe, today announced that Alvaro Torres, Khiron CEO and Director will lead a live, on-camera virtual tour of the Company's recently completed 15,000 square foot Zerenia integrated medical facility located in Bogota, Colombia.
Date: Tuesday, July 21st
Tour start: 9:00am ET
Participants: Alvaro Torres, Khiron CEO and Director, together with popular Colombia broadcaster Jorge Hernan Pelaez
This will be the first in a series of live, interactive events present by Khiron. Attendees are invited to ask the Company questions in real time, learn about the clinic operational model, meet members of the medical team, and discuss the Zerenia health and wellbeing advantages, including operations during the Covid-19 recovery. An archived recording will be available after the event.
Recent Company Highlights:
● Becomes the first and, to date, only company fully authorized to manufacture and sell high-THC medical cannabis for patient prescriptions in Colombia
● Signs distribution deal for its Kuida™ CBD cosmeceutical brand with Red Yellow Red, a leading EU distributor of cosmetic products, bringing the Kuida brand to the Spanish market
● Enters into an agreement with Nimbus Health, a leading German distributor of medical cannabis products to bring Khiron branded EU GMP medical cannabis to Germany
● Receives first medical cannabis prescriptions for patients participating in the UK's Project Twenty21, Europe's largest study of the effectiveness and tolerability of medical cannabis
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Contact Investorideas.com
800 665 0411
Wednesday, July 15, 2020
Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 441 (TSX: $AVCN.TO) (CSE: $IMCC.C) (OTC: $PSYC)
Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 441 (TSX: $AVCN.TO) (CSE: $IMCC.C) (OTC: $PSYC)
Delta, Kelowna, BC, July 15, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Read this in full at https://www.investorideas.com/news/2020/cannabis-potcasts/07151AVCN-IMCC-PSYC.asp
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we look at a few public and private company announcements.
Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products announced that its Rho Phyto™ product line of advanced medical cannabis products will be the subject of a Medical Cannabis Real-World Evidence study ("MC-RWE Study") led by Dr. Hance Clarke of the University Health Network ("UHN") in Toronto, Canada. The Rho Phyto products were developed in accordance with the recent Health Canada Cannabis 2.0 regulations that allow for more advanced, higher quality, medical cannabis product offerings. These products have been tested for prolonged stability, enhanced absorption, controlled delivery and other properties, in collaboration with Dr. Christine Allen's research group at the Leslie Dan Faculty of Pharmacy, University of Toronto.
The Rho Phyto medical cannabis product line is a full formulary that includes sublingual sprays, oil drops, capsules, and topicals of various cannabinoid ratios, namely THC and CBD.
By offering a variety of delivery systems, the medical community has the possibility to select the appropriate Rho Phyto product to suit a range of medical conditions such as pain relief, which may require either a fast onset of action or prolonged duration of effect over the course of treatment. The products are manufactured under good manufacturing practice ("GMP") in partnership with MediPharm Labs Inc. to ensure batch-to-batch consistency and high-quality products. The manufacture of the Rho Phyto products in accordance with GMP standard allows for data derived from this MC-RWE Study to provide early insights into Avicanna's ongoing and future directions of pharmaceutical development. Avicanna remains committed to patient safety and product consistency which is why all products subject to the MC-RWE Study are tested by Sigma Analytical and tracked by TruTrace Blockchain Technologies.
Dr. Justin Grant, Avicanna's Executive Vice President of Scientific Affairs commented, "After 3 years of collaborating with world-class Toronto-based researchers and clinicians including those at the University of Toronto and UHN, we are excited to offer the most consistent formulary of advanced medical cannabis products to prescribers and principal investigators, including Dr. Clarke, to further demonstrate the potential therapeutic efficacy of cannabinoids."
Avicanna's Rho Phyto products will be exclusively available to patients through the Medical
Cannabis by Shoppers online portal in addition to UHN clinicians through the MC-RWE Study by the end of July 2020. Additionally, Avicanna and Medical Cannabis by Shoppers are co-hosting a medical symposium in line with the launch of the Rho Phyto product line entitled, "MEDICAL CANNABIS 2.0: Advancements in Cannabinoid Research, Product Offerings and Patient Access". The symposium will be held on a virtual platform on July 21, 2020 and will include Dr Clarke's presentation "Real World Evidence and The Future of Medical Cannabis / Cannabinoid medicine for Pain Management" that will provide further insights on the MC-RWE Study. For registration and more information please visit (https://www.avicanna.com/symposium/).
The Health Depot Pharmacy and Lyte Medical announced their patient-centered online partnership; a venture that will help Canadians access medical care and prescriptions from the comfort and safety of their homes.
As Canadians adjust to a new reality and work to establish new daily routines; consistent access to healthcare and medications takes on even more importance. Virtual and direct-to-door prescription delivery are a necessity in meeting patients where they are.
According to the Canadian Radiotelevision and Telecommunications Commission, nationally, 86% of Canadian households have access to high speed internet. This online access presents health care practitioners and pharmacists with an opportunity to connect with patients remotely and remove some of the barriers to continuity of care including wait times, transportation, and scheduling.
In February 2020, The Canadian Medical Association, the Royal College of Physicians and Surgeons of Canada and the College of Family Physicians of Canada released a report on the future of virtual care in Canada. They emphasized the importance of prioritizing quality-based virtual care that truly respects the needs of Canadians.
"As a registered pharmacist since 2011, I have witnessed the evolution of health care in Canada. The Health Depot Pharmacy's partnership with Lyte Medical will allow Ontarians to see a physician and access their prescribed medications in a timely fashion", says Andy Donald, Founder & CEO of The Health Depot Pharmacy. "Our unique pharmacy services and approach allows necessary medications to be delivered promptly to those who rely on them, wherever and whenever they need them."
The Health Depot makes the pharmacy and healthcare shopping experience simple for all Ontarians. Their healthcare e-commerce store has thousands of health essentials available for online purchase and delivery, which can be shipped together with prescriptions for free.
Their Daily Dose Packs allow for an easy approach for patients who are taking multiple medications to have a simple, one daily packet approach, which is particularly helpful to seniors, caregivers, chronically ill, and individuals with special needs among others.
"Our forward thinking partnership with The Health Depot Pharmacy creates unprecedented access to a seamless virtual care experience. Canadians need medical care and medications in ways that accommodate their life circumstances", Ali Mohamed, CEO of Lyte Medical says. "Lyte Medical's virtual platform allows patients to speak to a doctor from the comfort of their own home and obtain their prescribed medications and health products online from The Health Depot Pharmacy, next day for free anywhere in Ontario with direct to door delivery."
Lyte Medical's patient friendly website makes connecting with a physician simple and easy. Lyte's comprehensive services include primary care, specialist referrals, mental health support, chronic pain treatment, and acute care. Patients will no longer have to take a day off from work, make childcare arrangements, or wait in line for their prescriptions, and for those living in rural areas, or vacationing at the cottage, The Health Depot and Lyte Medical will bring healthcare to Canadians at home, wherever that may be.
IM Cannabis Corp. (CSE: IMCC), a multi-country operator ("MCO") in the medical cannabis sector with operations in Israel and across Europe, announced that its German subsidiary, Adjupharm GmbH, has received a definitive purchase commitment of medical cannabis over the next twelve months from Zur Rose Pharma GmbH, an established distributor in Germany. This is the Company's fourth definitive purchase commitment with a distributor in Germany and advances IMC's strategy of creating a network of distribution partnerships to maximize penetration of IMC-branded products.
"We have now signed our fourth sales agreement with a binding purchase commitment. More importantly, we have added Zur Rose Pharma GmbH as a key partner, a well-established and reputable pharmaceutical service provider and wholesaler that bolsters our ability to provide quality medical cannabis products across the large and dynamic German market. As we continue to add trusted partners to our MCO network, we firmly believe that we have created a strong foundation to become the preeminent brand in international medical cannabis," said Oren Shuster, CEO of IMC.
"The momentum IMC has established within the German market is indicative of strong demand and favourable industry fundamentals for medical cannabis. With the launch of the IMC brand in Germany in Q3 2020, we have been deploying our sales teams to further physician education across the country and build our brand's reputation as a reliable provider of top quality medical cannabis to patients, pharmacists and physicians," added Richard Balla, CEO of Adjupharm.
Through its EU-GMP certified subsidiary, Adjupharm, the Company has entered into a three-year sales agreement with the medical cannabis distributor Zur Rose Pharma GmbH in Germany. This distributor has entered into a purchase commitment under its sales agreement.
IMC has also previously announced that Focus Medical Herbs Ltd. has signed six binding sales agreements for the distribution of IMC-branded medical cannabis products in Israel. Total consolidated revenue from all binding sales agreements in Israel is expected to be $193.5 million with an expected gross margin of 50%. A total of 33,075kg of medical cannabis will be delivered in Israel between Q2 2020 and 2023, and 3,000kg of medical cannabis under the sales agreements is expected to reach pharmacies in 2020.
Global Trac Solutions, Inc. (OTC: PSYC) announced the 2nd monthly release and distribution of the July edition of its Microdose Monthly newsletter, which features three articles that provide an overview of Kevin O’Leary’s investment participation with MindMed, a review of Gwyneth Paltrow’s Goop Lab on Netflix, and an exclusive one-on-one interview with Chi Psilocybin, a prominent voice for the psychedelic reform movement and owner of Truffles Therapy in Amsterdam.
The interview with Chi, amply titled “A Servant of the Mushroom Kingdom,” is an in-depth look at a personal journey and discovery of the benefits associated with a life-long affinity for psychedelics and finding life’s passion and purpose. On a trip to Thailand, Chi met his future wife and co-founder of their company, Truffles Therapy, a psilocybin retreat that has become his life’s work and has hosted many hundreds of “journeyers” from all over the world. Chi believes that everyone should have the opportunity to experience the magic of mushrooms.
David Flores, Global CEO, said, “I would like to personally thank Chi for taking the time to share his unique and fascinating story with us and for the voice he lends to the psychedelic reform movement taking place across the globe. Chi is playing a vital role in the industry’s continued emergence into society’s mainstream, which is showing great promise through clinical studies for treating debilitating mental health conditions, in addition to improving quality of life for millions across the globe. I believe that our subscribers are really going to enjoy this month’s latest newsletter written by Mr. Kent Sligh, Global’s Creative Content Director. Furthermore, I look forward to developing our network of industry leaders and advocates and exploring opportunities throughout this process to establish some of the strategic partnerships that will in time contribute to our emergence as an industry leader for news and information.”
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Contact Investorideas.com
800 665 0411
Subscribe to:
Posts (Atom)